Pfizer Collaboration to Tackle Drug-Resistant TB in China

7 April 2010 (Last Updated April 7th, 2010 18:30)

Pfizer has entered into collaboration with MicuRx and Cumencor Pharmaceuticals to discover novel therapeutic agents to treat multi-drug-resistant tuberculosis (MDR-TB). Under the agreement, Pfizer will provide upfront funding for the discovery and preclinical development of novel antibi

Pfizer has entered into collaboration with MicuRx and Cumencor Pharmaceuticals to discover novel therapeutic agents to treat multi-drug-resistant tuberculosis (MDR-TB).

Under the agreement, Pfizer will provide upfront funding for the discovery and preclinical development of novel antibiotics to treat MDR-TB, and payments based on the development and commercialisation of any antibiotics developed through the collaboration.

The World Health Organization estimates that China accounts for more than 25% of all worldwide cases of MDR-TB, mainly because of insufficient supervision and lack of adherence to therapeutic TB regimens.

Cumencor Pharmaceuticals is a China-based biotechnology company applying MicuRx's proprietary technology platform to discover and develop novel antibiotics for MDR-TB.

All collaboration research will be conducted at the ZhangJiang High-Tech Park in Shanghai, China.